Blog

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized…

More: 

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized…

Leave a Review

Please select a star rating
( Maximum Image Size : 100 KB )
Please enter valid youtube video url
Please write a review

Connect with

Facebook LinkedIn
OR

Tags: , , , , , , ,